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In osteosarcoma, knockdown of the parathyroid hormone-related protein (PTHrP) receptor reduces activation
through cyclic AMP-dependent protein kinase A (PKA) and substantially decreases tumor differentiation, invasion, and
proliferation in vivo. These ﬁndings complement other evidence supporting a central role of the PKA pathway in
osteosarcoma biology and pathogenesis.
Osteosarcoma (OS) is the fifth most
common cancer in children. Although
cytotoxic chemotherapy and improved
surgical approaches have increased the
overall long-term survival rate to 70%,
patients with metastatic disease have a sur-
vival rate lower than 20%. The biology of
OS has become the focus of recent atten-
tion, and an improved understanding
could lead to new pathways of treatment.
The role of parathyroid hormone receptor
(PTHR1) signaling in OS has never been
defined, nor indeed has that of PTH-
related protein (PTHrP). Our recent find-
ings suggest that PTHR1 acts to promote
tumor invasion and proliferation in OS.
Induction of OS in rats by radiophos-
phorus injection yielded tumors that were
markedly PTH-responsive.1 In that study,
removing the source of PTH by parathy-
roidectomy had no influence on any
aspect of OS, but that was many years
before the existence of PTHrP was appre-
ciated. Subsequent studies in OS cell lines
from several species have established PTH
responsiveness as a common, if not uni-
versal, feature of OS.2 PTHR1, a G-pro-
tein coupled receptor linked to adenylyl
cyclase, is activated by the N-terminal
regions of both PTH and PTHrP. PTHrP
was discovered as the factor responsible
for the humoral hypercalcemia of cancer,
and was found to act physiologically as a
paracrine/autocrine factor in many tissues,
including bone, where it is produced by
cells in the osteoblast lineage.3 There are 3
main subtypes of OS: osteoblastic, fibro-
blastic, and chondroblastic. Genetically
engineered mouse models of OS have
been used to generate the fibroblastic sub-
type by deletion of p53 and pRb from the
osteoblast lineage4, and the osteoblastic
subtype by shRNA-mediated knockdown
of p53 within the osteoblast lineage.5 Pri-
mary and metastatic tumors from either
subtype express functional PTHR1. OS
cultures of both subtypes responded to
treatment with either PTH or PTHrP
with the expected changes in gene expres-
sion5,6 and all expressed PTHrP.6
The functional relevance of PTHR1 to
OS biology has not been clearly defined in
vivo. Consistent with a role for PTHR1 in
OS, higher expression of PTHR1 mRNA
was detected in metastatic or relapsed
samples of a human OS series than in pri-
mary sites, and overexpression of PTHR1
in an OS cell line increased proliferation
and invasion.7 Knockdown of PTHR1 in
murine fibroblastic OS resulted in reduced
tumor cell invasion in vitro and changes in
gene expression that reflected loss of activa-
tion of PTHR1 and cAMP-dependent
protein kinase A (PKA).6 Notably, PTHR1
knockdown resulted in greatly reduced
proliferation and increased mineralization
of the tumor in vivo. PTHrP was present as
an intracellular protein in OS cells, but its
secretion was very low to undetectable.
Interestingly, treatment with a neutralizing
monoclonal antibody against PTHrP
failed to modify OS cell proliferation in
vitro or to influence tumor size in vivo.
Although the latter findings, together with
evidence for its nuclear localization in these
and in other cells,3 suggest that PTHrP
might be acting in an intracrine manner in
OS, in such a situation the action of
PTHrP on PTHR1 would be difficult to
explain. It seems more likely that an auto-
crine/paracrine action of PTHrP is respon-
sible and that the antibody is insufficiently
effective in this context.
The role of PKA activation in endo-
crine tumors is well known and the sub-
ject of recent interest in OS. In mice with
osteocalcin promoter-driven SV40T/t
antigen-induced OS, a subset of OS with
low expression of the a regulatory subunit
of PKA type I (PRKAR1A) was identi-
fied.8 This PRKAR1A-low OS was highly
invasive, leading to the conclusion that
Prkar1a is an OS tumor suppressor. The
functional consequence of reduced
PRKAR1A is enhanced PKA activity.
Consistent with a role of elevated PKA
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activity, an OS was identified with ampli-
fication of Prkaca, which encodes the cat-
alytic component of PKA, and Prkaca
RNA was shown to be overexpressed in
that tumor. It seems that enhanced PKA
signaling in OS might be mediated by
later events in the PKA/CREB cascade,
rather than strictly being ascribed to
Prkar1a as a tumor suppressor. Figure 1
illustrates changes in the PKA pathway
induced through these mechanism and
through PTHrP/PTHR1.
Also of interest is the observation that
loss of PRKAR1A increased the produc-
tion of receptor activator of nuclear factor
kB ligand (RANKL) in OS,8 whereas
upon PTHR1 knockdown the expression
of RANKL expression decreased and that
of osteoprotegerin (OPG) increased.6
Two aspects of RANKL biology are sig-
nificant in OS. It promotes both osteo-
clast formation, thereby favoring tumor
establishment and proliferation, and the
establishment and growth of metastatic
cancers in bone. Importantly, however,
there are also examples of osteoclastogen-
esis-independent effects of RANKL:
blockade of RANKL/RANK can inhibit
metastasis to bone by preventing cell
migration, and RANKL can promote
breast cancer metastasis to bone by a pro-
migratory effect through its receptor,
RANK, expressed on the cancer cells.9
Furthermore, in OS RANKL stimulated
both invasion through matrigel and
anchorage-independent growth, and each
of these effects was prevented by blockade
of the RANKL receptor.10
Taken together, these findings provide a
compelling case for a role of the
PTHrP!PTHR1!PKA axis in the main-
tenance of OS. If the driver through this axis
is indeed PTHrP, manipulating this
upstream target, for example through small-
interfering RNA or neutralizing antibodies,
could be used to regulate OS behavior.
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Figure 1. Alterations in the PTHrP!PTHR1!PKA pathway in osteosarcoma. (A) In normal osteoblasts, autocrine or paracrine parathyroid hormone-
related protein (PTHrP) binds and activates its receptor, PTHR1. Activation of PTHR1 causes the generation of cyclic AMP (cAMP) from ATP through
adenylyl cyclase. cAMP induces the dissociation of cAMP-dependent protein kinase (PKA) from its regulatory subunits, including the a regulatory subunit
of PKA type I (PRKAR1A). Once activated, PKA is able to move to the nucleus, where it phosphorylates and activates CREB. This leads to the activation of
target genes downstream of PTHR1 signaling. (B) In osteosarcoma cells, various aberrations in the PTHrP!PTHR1!PKA pathway that result in increased
activation of the PKA pathway have been described. 1. Elevated production of PTHrP that can bind PTHR1 and stimulate cAMP formation. 2. Increased
surface copy number of PTHR1. 3. Mutations in PRKAR1A that lead to increased PKA activity. 4. Ampliﬁcation of Prkaca, which encodes the catalytic com-
ponent of PKA.
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